L3VLUP
ProSign in

GMED · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

GMEDJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • GMED
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterGMEDJNJ
Q3 20208 holders, $639m30 holders, $26.2bn
Q4 20206 holders, $855m32 holders, $26.6bn
Q1 20217 holders, $779m31 holders, $25.3bn
Q2 202110 holders, $997m37 holders, $25.6bn
Q3 20219 holders, $871m40 holders, $24.1bn
Q4 202110 holders, $912m33 holders, $25.2bn
Q1 202210 holders, $934m35 holders, $28.2bn
Q2 20227 holders, $684m33 holders, $26.9bn
Q3 20226 holders, $781m36 holders, $25.4bn
Q4 20226 holders, $840m35 holders, $27.6bn
Q1 202315 holders, $720m42 holders, $24.5bn
Q2 202321 holders, $946m38 holders, $25.0bn
Q3 202317 holders, $881m37 holders, $18.9bn
Q4 202312 holders, $912m31 holders, $19.0bn
Q1 20248 holders, $772m32 holders, $19.7bn
Q2 202413 holders, $1.0bn35 holders, $20.4bn
Q3 202412 holders, $868m28 holders, $22.3bn
Q4 202414 holders, $1.4bn37 holders, $20.4bn
Q1 202513 holders, $951m32 holders, $20.5bn
Q2 202512 holders, $897m31 holders, $18.4bn
Q3 202511 holders, $765m32 holders, $23.7bn
Q4 202513 holders, $1.6bn29 holders, $27.8bn
Q1 202614 holders, $1.6bn34 holders, $35.6bn
Q2 202610 holders, $1.1bn33 holders, $39.1bn
GMED

Globus Medical Inc

Holders
12
Reported value
$897m
Buyers
10
Sellers
1

Breadth +9 among 95 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
JNJ

Johnson & Johnson

Holders
31
Reported value
$18.4bn
Buyers
15
Sellers
16

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 35 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only GMED (4)

Capital World Investors, Farallon Capital Management LLC, Freestone Grove Partners LP, Walleye Capital LLC

Only JNJ (23)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Fidelity (FMR LLC), Invesco Ltd, Markel Group Inc, Millennium Management LLC, Neuberger Berman Group LLC, Point72 Asset Management LP, Quantbot Technologies LP, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →